Abstract: A method for treating a cancer including administering to a subject in need thereof a complex of formula (I), where R1 is a substituted or unsubstituted cyclic amine, a ring of the cyclic amine has 5-7 atoms, R2 is a straight or branched aliphatic carbon chain including 3-10 carbon atoms, and X is a counter ion.

Abstract: Disclosed are methods and pharmaceutical compositions for treating and/or preventing hearing loss in a subject in need thereof. The disclosed methods typically utilize and the pharmaceutical compositions typical comprise an effective amount of a polyphenol therapeutic agent such as honokiol.

Abstract: A method of treating a COVID-19 infection including administering to a subject in need thereof an effective amount of a composition, where the composition includes silica nanoparticles, superparamagnetic iron oxide nanoparticles (SPIONs), chitosan, cisplatin, ribavirin, and an angiotensin-converting enzyme 2 (ACE-2). The SPIONs and ACE-2 are dispersed on an outer surface of the silica nanoparticles. The chitosan at least partially wraps around the outer surface of the silica nanoparticles. The cisplatin and ribavirin are in pores of the silica nanoparticles. The particles of the composition are monodisperse, and spherical, and have an average diameter of 70-100 nanometers (nm).

Abstract: The present disclosure relates to the use of an arsenic compound for treating a cytokine storm in a patient in need thereof.

Abstract: Compositions for preventing or decreasing cryptosporidiosis in animals are disclosed herein. The compositions include sources of hydrogen peroxide and are fed to animals. The animals may be neonatal calves and the cryptosporidiosis may be caused by Cryptosporidium parvum. Methods of preventing or decreasing cryptosporidiosis in animals by feeding the hydrogen peroxide-generating compositions to the animals are also disclosed. Some disclosed methods reduce the number of Cryptosporidium oocysts shed by an infected animal or reduce the infectivity of Cryptosporidium oocysts shed by an infected animal. Some methods include feeding the hydrogen peroxide-generating compositions to animals ultimately afflicted with cryptosporidiosis, and the animals gain weight despite the infection.

Abstract: Dendritic cells containing tumor lysate loaded particles are prepared. The dendritic cells present tumor antigens to elicit the Major Histocompatibility Complex class I pathway and can be used as a vaccine to treat cancer, including ocular melanoma.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating extrahepatic bile duct cancer containing, as active ingredients, natural killer (NK) cells and an anti-PD-1 antibody.

Abstract: The present invention relates to an anticancer T cell therapy product-assisting composition comprising a depleting anti-CD4 monoclonal antibody and a use thereof. Accordingly, the composition comprising a depleting anti-CD4 monoclonal antibody according to the present invention is able to maximize the anticancer effect of a cancer antigen-specific anticancer T cell therapy product by maintaining an immunodeficient state and is thus effective. In addition, when administered twice or more times at regular intervals of 5 to 8 days, the composition exhibits a far superior effect.

Abstract: The present application provides BCMA targeting chimeric antigen receptor (CAR) comprising a BCMA binding region and an intracellular costimulatory domain derived from DAP10. Further provided are engineered immune effector cells (such as NK cells) comprising the chimeric antigen receptors. Pharmaceutical compositions, kits and methods of treating cancer are also provided.

Abstract: This present invention relates to BCMA binders (e.g. antibodies) and chimeric antigen receptor (CAR) constructs comprising a BCMA antigen binding molecule. The BCMA binders specifically bind to BCMA. The present BCMA CARs further comprise a hinge region (e.g., CD28 hinge), a transmembrane domain, and one or more intracellular NK cell signalling domains. NK cells expressing a BCMA CAR has increased efficacy in killing cancer cells. Provided herein also include therapeutic uses of the BCMA binders and BCMA CARs.

Abstract: The present application provides modified immune cells that express TLR receptors. In some embodiments, the modified immune cell further comprises an engineered receptor such as a chimeric antigen receptor (CAR). The present application also provides methods and pharmaceutical compositions for cancer treatment using the modified immune cells described herein.

Abstract: The present application provides methods and compositions for treating cancers using a CAR T cell therapy platform. Also provided are methods and use of the CAR T cells for treating diseases and conditions, such as cancer, and in particular any disease or condition associated with elevated adenosine or other associate marker.

Abstract: The presently disclosed subject matter provides cells, compositions and methods for enhancing immune responses toward tumor. It relates to cells comprising: an antigen-recognizing receptor (e.g., a chimeric antigen receptor, a TCR, or a TCR like fusion molecule), a Fas ligand polypeptide (FasL), and a gene disruption of a Fas locus. The gene disruption of the Fas locus can improve the activity and/or efficiency of the cells. The presently disclosed cells, compositions, and methods can be used in allogeneic settings.

Abstract: Embodiments of various aspects described herein relate to methods, kits, and cell culture media for generation of podocytes from pluripotent stem (PS) cells, as well as cells produced by the same, and methods of use.

Abstract: The present disclosure provides methods for treating hypoplastic left heart syndrome in patients in need thereof, the methods involving the administration of a therapeutically effective amount of mesenchymal stem cells. The methods may further involve measuring various biomarkers related to cardiac health and function after administration of the mesenchymal stem cells to determine both the efficacy of the treatment and whether more mesenchymal stem cells need to be administered for a therapeutic effect to occur.

Abstract: Disclosed herein are compositions, methods, and kits for use in treating hematopoietic malignancies, the compositions, methods, and kits comprise a cytotoxic agent targeting cells expressing a lineage-specific cell-surface protein and a population of hematopoietic cells that express the lineage-specific cell-surface protein, the hematopoietic cells being manipulated such that they do not bind the cytotoxic agent.

Abstract: Compositions and methods are disclosed herein for the treatment of aging frailty with bone marrow derived mesenchymal stem cells. The methods of treatment involve the administration of a composition of bone marrow derived mesenchymal stem cells to a subject in need thereof, wherein the effectiveness of the treatment methods can be determined through the measurement of specific biomarkers and improved physical activity.

Abstract: The present invention aims to provide a therapeutic composition, particularly a composition for transplantation therapy, which can be cryopreserved, does not cause damage to cells due to thawing, and can be administered to a patient as is without undergoing additional processes such as washing or centrifugation of cells after thawing. A therapeutic composition for transplantation containing a corneal endothelial substitute cell having a CD24-positive phenotype, phenolphthalein derivative, and a cryoprotective agent. Such therapeutic composition can be safely transplanted into the chamber of the eye, even though it contains a cryoprotective agent. Since it is CD24 positive, it can be expected to have an effect of avoiding phagocytosis.

Abstract: Aspects of the present invention include compositions and methods for discovering novel compositions and applying said compositions in treating medical conditions including aging, degenerative disease, and cancer through the modulation of molecular pathways regulating regeneration and senolysis by means of altering the embryonic-fetal and prenatal/postnatal transitional states of mammalian cells.

Abstract: This invention relates generally to the discovery of novel mammalian lung spheroids and lung spheroid cells and uses thereof.

Abstract: Disclosed is a production method of a product that is developed for treatment of hair loss, alopecia areata (pelade or ringworm), androgenetic alopecia (AGA), hair follicle nourishment, scalp nourishment and scar, scar tissue, eczema, acne treatments, for neurodegenerative, inflammatory diseases and for immune modulation purposes (regulation of the immunological response against inflammation of human tissues and fluids, for regeneration purposes). In particular, the disclosed is a method for the production of a chemical-free product with amniotic fluid content, which has been standardized by pooling and then freeze-dried and gamma irradiated (pooled/cocktail and gamma irradiated amnion-OTIA 1.0), that has been developed to be used in the treatment of ailments such as hair loss, alopecia areata (pelade), androgenetic alopecia (AGA), hair follicle nutrition, scalp nourishment, scar, scar tissue, eczema and acne.

Abstract: The present invention provides to compositions comprising cord blood platelet-rich plasma (CB-PRP) for the treatment of ocular diseases as well as methods of treatments of ocular diseases in which therapeutic effective amounts of blood platelet-rich plasma (CB-PRP) are administered to a subject in need thereof.

Abstract: An anti-viral composition or formulation is described that includes free fatty acids (“FFA”). Also described, are methods of making and using such a composition or formulation.

Abstract: A nutritional supplement containing fish oil and selenium has been identified that reduces inflammation. A formulation for such a supplement that is both well tolerated and palatable is also provided.

Abstract: Provided herein are multi-strain population control systems, methods, kits, and compositions. Also provided are methods, systems, kits, and compositions for culturing bacterial cells in multi-strain ecosystems, and temporally arranged multi-strain ecosystems or cultures using a synchronized lysis circuit in combination with multiple toxin/antitoxin systems to cycle continuously over a long period of time.

Abstract: Disclosed are compositions comprising pasteurized Akkermansia for the treatment or prevention of gut contractility disorders, in particular for reducing the duodenal amplitude of contractions.

Abstract: The present invention relates to a composition comprising one or more isolated probiotic bacterial strains, two or more active of the one or more isolated probiotic bacterial strains, or the combination of one or more isolated probiotic bacterial strains and two or more active of the one or more isolated probiotic bacterial strains; and an acceptable carrier, wherein the one or more isolated probiotic bacterial strains and/or the two or more active of the one or more isolated probiotic bacterial strains is capable of inhibiting fungal proliferation.

Abstract: Compositions and methods of use for modulating bile acids, including phenylalanocholic acid, tyrosocholic acid and leucocholic acid, to treat diseases, such as inflammatory bowel disease.

Abstract: The present invention relates to new strains of Enterococcus sp., in particular, inflammatory and non-inflammatory strains of Enterococcus sp., useful for bacterio therapy.

Abstract: A composition with NRF mitochondria activating ingredient has telomere extension, anti-aging and cell-rejuvenating effects, including salvia miltiorrhiza extract, wheat ?-amylase inhibitor, and probiotic powder. After taken by users, the composition reaches a health effect by extending the telomere length and to reduce the cell age and get younger.

Abstract: The present invention provides use of a Bifidobacterium lactis supernatant as a bifidogenic factor. The present invention also provides a Bifidobacterium lactis supernatant for use in enhancing the growth of bifidobacteria in the gastrointestinal tract of a subject. The present invention also provides a Bifidobacterium lactis supernatant for use in treating or preventing a gastrointestinal disease by enhancing the growth of bifidobacteria in the gastrointestinal tract of a subject.

Abstract: Provided are a Lactobacillus plantarum against Helicobacter pylori infection and the use thereof. The Lactobacillus plantarum against Helicobacter pylori infection is named Lactobacillus plantarum Lp05 and was deposited in the China General Microbiological Culture Collection Center on 9 Oct. 2021, with the deposit number CGMCC No. 23547. Further provided are a method for culturing the Lactobacillus plantarum against Helicobacter pylori infection and a product for inhibiting Helicobacter pylori infection. The Lactobacillus plantarum against Helicobacter pylori infection of the present application has good gastric acid resistance, inhibits the proliferation of Helicobacter pylori, and reduces the adhesion effect of Helicobacter pylori to gastric epithelial cells, thereby creating conditions for the eradication of Helicobacter pylori. The product for inhibiting Helicobacter pylori infection does not cause adverse reactions nor drug resistance of pathogenic bacteria.

Abstract: The present invention relates to at least one strain of bacteria belonging to the species Lactobacillus paracasei, preferably Lactobacillus paracasei DG® CNCM I-1572 and/or Lactobacillus paracasei LPC-01 DSM 26760, and compositions thereof for use in newborns and/or from 1 month to ?12 months subjects in the treatment, preventive and/or curative, of gastro-intestinal tract disorders of an inflammatory and/or functional nature, gastro-intestinal infections by pathogenic micro-organisms, gastro-intestinal infections by parasites, allergies, immune-mediated or autoimmune disorders, and in the support of the subject's growth.

Abstract: The present disclosure relates to a natural water-soluble plant compound with antidepressant and sleep-promoting effects, and a preparation method and use thereof. In the present disclosure, the preparation method includes: immersing Fructus lycii, green tea, spina date seed, lily, sugarcane, peanut stem, Euglena, and Chlorella in water, and conducting ultrasonication and first solid-liquid separation to obtain a plant extract; mixing the plant extract with an organic extractant to extract an extracted aqueous phase; removing a solvent of the extracted aqueous phase to obtain a crude extract; dispersing the crude extract into water, and conducting second solid-liquid separation to obtain a purified water extract; and drying the purified water extract to obtain the natural water-soluble plant compound.

Abstract: The present invention provides nutritional compositions that are employed as oral supplementation to the human diet and methods for using such nutritional compositions. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer.

Abstract: A method and related topical skin preparation comprising an extract from Ephedra viridis. The disclosed method and preparation treat fever blisters caused by herpes simplex virus and other skin-related inflammatory conditions.

Abstract: Cosmetic and pharmaceutical formulations comprising specific amino acid combinations are described herein. Such formulations strengthen and enhance skin epithelial cell barrier function, thereby reducing moisture loss from the skin and restoring skin's structural integrity, epithelial differentiation, intercellular adhesion, and intracellular signaling and/or promoting maintenance of these features. Additional formulations described here comprise a therapeutically effective amount of free amino acids and a therapeutically effective amount of a plant extract for skin barrier repair. Methods for administering these formulations for cosmetic and/or therapeutic purposes and uses thereof for same are also described herein, including the use thereof in the preparation of medicaments.

Abstract: Enhanced cannabinoid compositions and methods for producing enhanced cannabinoid compositions are provided. The method can include winterizing a Cannabis extract. wherein the winterizing comprises mixing the Cannabis extract with a solvent at a temperature below ?20 C; permitting separation of components of the extract for a period of time sufficient for an insoluble lipid fraction to separate from soluble components; collecting the insoluble lipid fraction; refining the lipid fraction; and/or adding an amount of refined lipid fraction to the composition; The amount of refined lipid fraction can be sufficient to result in an enhanced characteristic of the composition.

Abstract: The pharmaceutical composition for treating or preventing neuropathic pain includes Polygonati rhizoma, Sorbus commixta Hedl., Geranium nepalense, and Glycine Semen Preparata.

Abstract: Compositions comprising phenolic phytochemicals of oregano, cranberry, or Rhodiola are provided. Compositions comprising a polymer, clay, and the phenolic phytochemicals are also provided. Methods of using the phenolic phytochemical compositions to treat a subject with bone metastasis are also provided, particularly methods of treating bone metastasis from breast or prostate cancer.

Abstract: A plant extract for alleviating pulmonary fibrosis, and a preparation method and a use thereof are provided. The preparation method includes the following steps: (1) crushing Aronia melanocarpa (Michx.) Elliott berries after drying, mixing the crushed berries with ethanol for soaking and extraction, and filtering the mixture to obtain an extract solution of Aronia melanocarpa (Michx.) Elliott; (2) crushing Cynara scolymus L. buds after drying, mixing the crushed buds with ethanol for extraction, and filtering the mixture to obtain an extract solution of Cynara scolymus L.; (3) crushing Brassica oleracea var. albiflora Kuntze roots after drying, and mixing the crushed roots with ethanol for ultrasonic extraction to obtain an extract solution of Brassica oleracea var. albiflora Kuntze; (4) mixing the extract solutions of Aronia melanocarpa (Michx.) Elliott, Cynara scolymus L. and Brassica oleracea var. albiflora Kuntze to obtain the plant extract for alleviating pulmonary fibrosis.

Abstract: The present disclosure relates to a method for lowering blood sugar including administering an effective amount of a green tea peptide composition to a subject in need thereof, and specifically, the green tea peptide composition according to the present disclosure exhibits a blood sugar-lowering effect through excellent stimulation of glucose transport in adipocytes, inhibition of gluconeogenesis in hepatocytes, and DPP-4 inhibitory activity, and can be applied to various health functional food compositions and pharmaceutical compositions.

Abstract: The disclosure generally describes methods of preventing or treating dominant optic atrophy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof. The present technology relates generally to the treatment or prevention of Leber's hereditary optic neuropathy (LHON) or dominant optic atrophy (DOA) in mammals through administration of therapeutically effective amounts of aromatic-cationic peptides to subjects in need thereof. In one aspect, the present disclosure provides a method of treating or preventing dominant optic atrophy in a mammalian subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide.

Abstract: Provided herein is a method for improving functional outcomes of a spinal cord injury in a subject in need thereof, comprising administering to said subject an effective amount a peptide of Formula I, or a pharmaceutically acceptable salt thereof. Such functional outcomes may include, but are not limited to, motor, sensory, and autonomic physiological functions.

Abstract: Methods of treating a fungal contamination are disclosed. Methods of eliminating or inhibiting proliferation of a target fungal organism at a target site are also disclosed. The methods include administering a thermally stable preparation comprising a purified amphiphilic peptide in a biocompatible solution and administering a buffer to a target site. The peptide has a folding group having a plurality of charged amino acid residues and hydrophobic amino acid residues arranged in a substantially alternating pattern and a turn sequence. The peptide is configured to self-assemble into a hydrogel.

Abstract: Embodiments are directed to a method of treating acute radiation syndrome comprising administering to a subject following exposure to radiation a PIF peptide. Some embodiments describe a method of treating acute radiation syndrome following radiation exposure comprising transplanting bone marrow that has been exposed to a PIF peptide prior to transplantation into a subject. Other embodiments describe a method of increasing engraftment of a transplanted organ, tissue, or cell by pre-exposing the organ, tissue, or cell to a PIF peptide.

Abstract: A method for reducing, inhibiting, preventing or treating cytotoxicity in a cell, the method comprising expressing or overexpressing in the cell a Rho guanine nucleotide exchange factor (RGNEF), or a RGNEF analog or agonist, or a leucine rich domain of RGNEF, whereby the cytotoxicity in the cell is reduced, inhibited, prevented or treated. Also a method of shifting the survival curve of a subject and thereby increasing life expectancy of the subject by administering to the subject a physiologically effective amount of a peptide comprising A Rho Guanine Nucleotide Exchange Factor (RGNEF) protein, or a RGNEF analog or agonist, or a leucine rich domain of RGNEF, or expressing or overexpressing RGNEF or a RGNEF analog or agonist or a leucine rich domain of RGNEF in the subject.

Abstract: A method for preventing or reversing at least one of photoreceptor outer segment disruption. RPE lipid deposition, neurodegeneration, and any combination thereof in a patient in need is disclosed. The method includes administering a therapeutically effective amount of a composition comprising ApoM.

Abstract: Disclosed in the present invention are: a pharmaceutical composition for preventing or treating fibrotic diseases, comprising hyaluronan and proteoglycan link protein 1 (HAPLN1) or a gene encoding same as an active ingredient; and a method for preventing or treating fibrotic diseases using the composition. According to the present invention, fibrosis of cells or tissues is prevented and inhibited such that the occurrence or progression of various kinds of diseases caused by fibrosis is fundamentally suppressed, and thus the diseases can be prevented or treated.

Abstract: Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.